The U.S. Food and Drug Administration (FDA) has granted expedited approval to a new drug aimed at treating advanced pancreatic cancer, marking a significant development in combatting one of the most lethal cancer types. The medication, known as daraxonrasib and marketed under the brand name Rasonque by Revolution Medicines, is the first drug to directly target mutations in the RAS gene family—mutations present in over 90% of pancreatic cancer cases.
Pancreatic cancer has long been a challenging disease to treat, partly due to late detection and its aggressive progression. Survival rates have remained low, with a five-year overall survival rate of approximately 13%. The new treatment offers renewed hope for patients with metastatic pancreatic cancer that no longer responds to chemotherapy.
Revolution Medicines’ approval follows the results of a company-sponsored clinical trial involving 500 patients. Those receiving Rasonque experienced a median survival time of 13.2 months, nearly double the 6.7 months seen in patients who continued chemotherapy alone. The drug functions by blocking the mutated KRAS protein, which drives tumor growth. This has been a major scientific hurdle because the mutated protein’s structure was previously considered “undruggable” due to its flat surface lacking a typical binding site for drugs.
Despite its benefits, Rasonque is associated with side effects, including skin rashes, mouth sores, diarrhea, and other gastrointestinal issues. Former U.S. Senator Ben Sasse, who participated in clinical trials, publicly shared his experience with significant tumor reduction accompanied by visible skin reactions.
The new medication is administered orally as a daily pill, with a monthly cost nearing US$40,000. While this represents a substantial financial burden, analysts anticipate Rasonque could generate annual sales exceeding US$20 billion if further studies confirm its effectiveness in treating earlier-stage pancreatic cancer or other cancer types.
Experts in the oncology community have welcomed the approval as an important step forward. Dr. Andrew Coveler of the Fred Hutch Cancer Center described the medication as a “significant improvement” for patients, though not a cure, while Dr. Pashtoon Kasi of City of Hope Orange County highlighted the potential for this breakthrough to open doors for additional targeted therapies against various tumors.
The drug’s development traces back to efforts in the early 1980s to understand cancer-causing gene mutations. Pioneering research identified the RAS gene family as a key driver in multiple cancers, but decades of drug development struggled to create effective treatments. Innovations involving “molecular glues” that help drugs bind to challenging proteins eventually led to the creation of daraxonrasib.
FDA officials accelerated the approval process, finalizing the decision more than six months ahead of schedule. Acting FDA commissioner Kyle Diamantas emphasized the agency’s commitment to delivering meaningful treatments swiftly to patients facing serious illnesses.
While Rasonque represents a promising advancement for pancreatic cancer therapy, ongoing research and clinical trials will be pivotal in determining its role in broader cancer treatment regimens.